Esperion Therapeutics, Inc. (ESPR)
After hours:
| Previous close | 5.92 |
| Open | 6.14 |
| Bid | 5.90 x 2200 |
| Ask | 6.04 x 1100 |
| Day's range | 5.84 - 6.27 |
| 52-week range | 3.28 - 8.87 |
| Volume | |
| Avg. volume | 1,953,956 |
| Market cap | 440.14M |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.24 |
| Earnings date | 20 Feb 2023 - 24 Feb 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.60 |
- Simply Wall St.
The past five years for Esperion Therapeutics (NASDAQ:ESPR) investors has not been profitable
Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow...
- GlobeNewswire
RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
NASCAR Champion Brad Keselowski to Run No. 6 NEXLIZET (bempedoic acid and ezetimibe) Ford in Famed Daytona 500CONCORD, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year agreement pursuant to which Esperion will promote two cholesterol lowering treatments – NEXLIZET (bempedoic acid and ezetimibe) and NEXLETOL (bempedoic acid). NEXLIZET will be featured on Keselowski’s N
- Zacks
PTC Therapeutics (PTCT) Soars 5.8%: Is Further Upside Left in the Stock?
PTC Therapeutics (PTCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
